Cargando…
Pembrolizumab-induced large duct cholangiopathy: Diagnosis and follow-up imaging
Immune-checkpoint inhibitor mediated hepatobiliary injury is an emerging concern in cancer treatment. Most of these adverse reactions are attributed to nivolumab and are characterized by panlobular hepatitis. Large duct cholangiopathy related to these drugs is extremely rare. We present a case of ad...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098868/ https://www.ncbi.nlm.nih.gov/pubmed/33533751 http://dx.doi.org/10.4103/jpgm.JPGM_793_20 |